Originally published In Press as doi:10.1074/jbc.M001368200 on May 8, 2000
J. Biol. Chem., Vol. 275, Issue 31, 23559-23568, August 4, 2000
Mutation of Ha-Ras C Terminus Changes Effector Pathway
Utilization*
Michelle A.
Booden
§,
Donald S.
Sakaguchi§¶, and
Janice E.
Buss
§
From the
Department of Biochemistry, Biophysics, and
Molecular Biology, ¶ the Department of Zoology/Genetics, and
the § Signal Transduction Training Group, Iowa State
University, Ames, Iowa 50011
Received for publication, February 18, 2000, and in revised form, May 2, 2000
 |
ABSTRACT |
In PC12 cells, Ha-Ras modulates multiple effector
proteins that induce neuronal differentiation. To regulate these
pathways Ha-Ras must be located at the plasma membrane, a process
normally requiring attachment of farnesyl and palmitate lipids to the C terminus. Ext61L, a constitutively activated and palmitoylated Ha-Ras
that lacks a farnesyl group, induced neurites with more actin
cytoskeletal changes and lamellipodia than were induced by farnesylated
Ha-Ras61L. Ext61L-triggered neurite outgrowth was prevented easily by
co-expressing inhibitory Rho, Cdc42, or p21-activated kinase but
required increased amounts of inhibitory Rac. Compared with Ha-Ras61L,
Ext61L caused 2-fold greater Rac GTP binding and phosphatidylinositol
3-kinase activity in membranes, a hyperactivation that explained the
numerous lamellipodia and ineffectiveness of Rac(N17). In contrast,
Ext61L activated B-Raf kinase and ERK phosphorylation more poorly than
Ha-Ras61L. Thus, accentuated differentiation by Ext61L apparently
results from heightened activation of one Ras effector
(phosphatidylinositol 3-kinase) and suboptimal activation of another
(B-Raf). This surprising unbalanced effector activation, without
changes in the designated Ras effector domain, indicates the Ext61L
C-terminal alternations are a new way to influence Ha-Ras-effector
utilization and suggest a broader role of the lipidated C terminus in
Ha-Ras biological functions.
 |
INTRODUCTION |
Ras proteins are monomeric GTP-binding proteins that operate as
inducers of signal transduction cascades regulating cell growth and
development (1). They cycle between the GDP-bound inactive and the
GTP-bound active form. In their active form, Ras proteins interact with
and modulate the activity of effector proteins, including Raf kinases,
phosphoinositide 3-kinase
(PI3-kinase),1 Ral guanine
nucleotide dissociation stimulator, and AF6 (2-7). These
proteins initiate multiple signal transduction cascades that must occur
cooperatively to produce a full biological response (8). Effector
proteins bind to a small region of Ras termed the effector domain (9),
whose core is comprised of residues 32-40. This region is also known
as Switch I, as its conformation, along with that of an additional
Switch II region (residues 61-77), changes substantially when Ras
proteins bind GTP (10).
In addition to GDP/GTP cycling, another requirement for Ras activity
involves the correct localization of Ras proteins to the inner surface
of the plasma membrane. Plasma membrane binding of Ras is critical for
its function because, at least in part, this allows Ras to target its
effector proteins to the location where they encounter their substrates
or can be activated (11). Newly synthesized Ras proteins are
partitioned to the cytoplasmic face of the plasma membrane by a series
of post-translational lipid modifications of the C terminus of the
protein (12). The first lipid to be attached, a farnesyl group, appears
to initiate membrane binding. Recent studies indicate that the
endoplasmic reticulum is likely to be the site of first contact,
followed by further trafficking to the plasma membrane that occurs
through as yet unstudied pathways (13). For Ha-Ras, farnesylation of Cys186 is followed by the addition of palmitates to two
adjacent cysteine residues (Cys181 and Cys184).
Native Ha-Ras proteins with all C-terminal cysteines and lipids present
are >95% membrane-bound at steady state, whereas Ha-Ras proteins that lack cysteines at 181 and 184 and thus have a farnesyl group as the only lipid are >90% cytosolic (14-17). In addition to
the lipids' roles in Ha-Ras targeting and stable association with the
plasma membrane, the amino acids of the C terminus also appear to be
involved in trafficking of Ha-Ras from the endoplasmic reticulum to the
cell surface (17).
An important yet unresolved issue is whether the lipids or residues of
the C-terminal region make a further contribution to Ha-Ras function by
directly supporting interactions with specific effectors. Recent
studies show that farnesyl modification of Ha-Ras is important for high
affinity interaction with (18, 19) and full kinase activity of Raf-1
(20-22). Farnesylation is also reported to increase in
vitro binding of Ha-Ras and KRas4B to p110
, a PI3-kinase
catalytic subunit family member (23). Earlier studies employing a
constitutively activated yeast Ras2 protein indicated that interaction
between Ras2 and adenylyl cyclase is decreased in the absence of the
farnesyl lipid modification (24, 25). A possible role in effector
interaction for the lipids and C-terminal amino acids of Ras proteins
is also implied by recent work reporting that Ha- and K-Ras proteins
differ in their ability to activate Raf-1 and PI3-kinase (26, 27). The
major differences between the Ha-Ras and KRas4B proteins are confined
to their post-translational lipid modifications and their last
twenty-five amino acids. Although both proteins are farnesylated,
Ha-Ras is modified by palmitates that are attached to cysteines 181 and
184, whereas KRas4B contains no palmitates and has instead a polybasic
domain (lysine residues 175-180). Taken together, these data suggest
that the C terminus of Ras proteins may provide a mechanism (in
addition to that of the internal classical effector domain) for
influencing effector interactions.
In previous work we had characterized Ext61L, a constitutively
activated Ha-Ras protein in which the C-terminal residue of the
CAAX motif for farnesylation was replaced with six lysines (28). This design prevented attachment of the farnesyl group but
retained the natural sites for palmitoylation at the C terminus. The
novel lipidation state of Ext61L presented a new way to determine if
the absence of a farnesyl group impaired any signaling pathways, in a
protein that was acylated and maintained an interaction with membranes
through its C terminus. A shift in Ha-Ras function had already been
noted with Ext61L. Expression of the protein in PC12 cells caused an
unusual morphological differentiation distinct from that induced by
Ha-Ras61L with the native C terminus. Importantly, no changes had been
made in the effector binding domain of Ext61L, and its GTP binding
properties were preserved (28), indicating that these primary
requirements for effector interaction were unaltered. Here we describe
results that suggest that the accentuated differentiation produced by
Ext61L results from heightened activation of one Ras effector (PI-3
kinase) and suboptimal activation of another (B-Raf). These
observations lend support to the idea that Ras-effector interactions
may be influenced, in addition to the GTP-sensitive switch regions of
the protein, by the C-terminal domain.
 |
MATERIALS AND METHODS |
Plasmids and Transfections--
Construction of Ha-Ras61L and
Ext61L in the pcDNA3 vector has been described previously (28).
Amounts of plasmid DNA (in brackets) were titrated so that equivalent
amounts of Ha-Ras61L (1 µg of DNA), Ext61L (50 ng of DNA), Ha-Ras (1 µg), or ExtWT (1 µg) proteins were produced in the P100/membrane
fraction of transfected cells. Plasmids driving expression of Myc- or
hemagglutinin (HA)-epitope-tagged versions of the truncated protein
Myc-PAK1-(165-205) (3 µg of DNA) (29) or full-length
Myc-Cdc42(17N) (1 µg of DNA), Myc-Rac1(17N) (1 µg or 3 µg of
DNA), or HA-Rac1 (7 µg of DNA) were kindly provided by Gary Bokoch
(La Jolla, CA).
p85 (1 µg of DNA) and Myc-RhoA(14V) (1 µg of
DNA) in the pEXV3 vector have been described elsewhere (30) and were
gifts from Gideon Bollag (Richmond, CA) and Lawrence Quilliam
(Indianapolis, IN). Wild type B-Raf and inositol 4-phosphatase
(4-PTase) in the pcDNA3 vector were gifts from Geoff Clark
(Bethesda, MD) and F. Anderson Norris (Ames, IA), respectively. The MEK
inhibitor PD98059 and the PI3-kinase inhibitor LY294002 were purchased
from Calbiochem and used at a concentration of 50 µM.
Twenty-four hours before transfection, 1 × 105 PC12
cells were plated onto 60-mm tissue culture dishes coated with laminin (10 µg/ml; Life Technologies, Inc.) and grown overnight. These PC12
cells are derived from an early clone of the original isolate (generously provided by J. H. Pate Skene, Duke University), and if
continuously subcultured before reaching high cell density, show high
transfection efficiency and very low (<1%) spontaneous neurite
extension. Transfections were performed using the LipofectAMINE reagent
(Life Technologies, Inc.) as described by the manufacturer. For most
experiments the total amount of DNA added to each plate was adjusted to
5 µg using empty pcDNA3 vector DNA. For Rac-GTP binding assays a
total of 8 µg of DNA (7 µg of Rac1 + 1 µg of a combination of
empty vector and Ha-Ras DNA) was added per dish. Quantitation of the
percentage of cells bearing neurites was performed on day 2 when
neurites could still be accurately assigned to a particular cell body.
Pictures of differentiated cells were taken, and biochemical assays
were performed on day 4 when the morphological differences between
cells expressing Ha-Ras61L and Ext61L were most distinct and when
neurites in both types of Ras-transfected cells were well established.
The efficiency of transfection was measured by co-transfection of cells
with a
-galactosidase expression plasmid (26) and by counting the
percent of cells producing an immunofluorescence signal for Ha-Ras
(below). Both methods showed that in cultures that were subjected to
transfection, 60-70% of the cells expressed the transfected Ha-Ras
protein and that 92-95% of these transfected cells expressed
neurites. Expression of either cellular (wild type) forms or the
activated Myc-RhoA(19N), Myc-Rac1(12V), or Myc-Cdc42(12V) proteins
failed to promote PC12 neurite formation (data not shown) showing, as
had been reported previously, that expression of these proteins
individually is not sufficient to produce the complex response of
neural differentiation (31, 32). Immunoblots using monoclonal
antibodies to the HA epitope (Babco, MMS-101R) or to the Myc epitope
tag (Santa Cruz Biotechnology, 9E10) confirmed that the dominant
negative, cellular, and constitutively activated proteins were
expressed (see Figs. 2B and 3; other data not shown).
Immunofluorescence--
PC12 cells were plated on laminin-coated
18-mm coverslips in serum-containing medium. Within 24 h of
plating, the cells were transfected as described above and cultured for
4 days. The cells were then washed in phosphate-buffered saline and
fixed in fresh 4% paraformaldehyde in 0.1 M phosphate
buffer for at least 30 min at room temperature. Cell membranes were
permeabilized by incubation of cells in 0.2% Triton X-100, 5% goat
serum, and 0.4% bovine serum albumin in phosphate-buffered saline for
20 min at room temperature. To visualize the F-actin cytoskeleton,
rhodamine isothiocyanate-phalloidin (Molecular Probes) in
phosphate-buffered saline (1 ml of a 1/400 dilution) was added to each
coverslip. After a 20-min incubation, coverslips were washed five times
in phosphate-buffered saline, and the coverslips were mounted on a
glass slide with Vectashield (Vector Laboratories). Detection of cells
expressing Ha-Ras was performed by immunofluorescence using monoclonal
antibody Y13-238 (Santa Cruz Biotechnology) at a 1/1000 dilution.
Fluorescence was detected with a Nikon FXA microscope equipped with a
60× oil objective (1.0 numerical aperture), and images were captured
with a Kodak Megaplus 1.4 CCD camera (Kodak Corp.) connected to a
Perceptics MegaGrabber framegrabber (Perceptics Corp.) in a Macintosh
8100/80AV computer using NIH Image. Figures were prepared using Adobe
Photoshop 4.0 and Macromedia Freehand Version 8.0 for the Macintosh.
Preparation of Subcellular Fractions, Co-immunoprecipitation, and
Immunoblotting--
Cytosol and crude membrane fractions were
separated by hypotonic lysis and high speed centrifugation as described
(33). For detection of interaction between Ha-Ras and PI3-kinase, the P100 membrane-containing pellets were dissolved in buffer A (20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM
EDTA, 0.3 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride, 1% Triton X-100, 10 µg/ml aprotinin,
and 10 µg/ml leupeptin). The S100 cytoplasmic fractions were adjusted
to the composition of buffer A and Ha-Ras or PI3-kinase immunoprecipitates formed as described (34) with 150 µg of total protein from each fraction, as determined using the DC Protein Assay
kit (Bio-Rad). To learn if detergent-resistant membranes (DRMs) were
preserved in the chilled 1% Triton X-100 buffer used for
immunoprecipitation, any domains were solubilized, and proteins were
released by warming the dissolved lysates for 2 min at 37°, followed
by normal formation and washing of the immunoprecipitates (35). In
addition, the protein concentration in these samples was 150 or 300 µg/ml, far less than the 5 mg/ml needed to retain DRM integrity. To
detect interaction between Ha-Ras and B-Raf, P100 membrane pellets were
dissolved in buffer B (70 mM
-glycerophosphate (pH 7.2),
100 µM Na3VO4, 2 mM
MgCl2, 1 mM EGTA, 0.5% Triton X-100, 1 mM dithiothreitol, 5 µg/ml leupeptin, and 20 µg/ml
aprotinin). The S100 fractions were adjusted to the composition of
buffer B (36), and 150 µg of total protein from each fraction were used to form either Ha-Ras or B-Raf immunoprecipitates. Ha-Ras, B-Raf,
or PI3-kinase proteins were immunoprecipitated using anti-Ha-Ras rat
monoclonal antibody (3E4-146, Quality Biotech), anti-p85
rabbit
polyclonal serum (06-195, UBI), or anti-B-Raf rabbit polyclonal serum
(C19, Santa Cruz Biotechnology). Immunoprecipitates were captured on
protein G-agarose beads (Life Technologies, Inc.), washed three times
in their respective lysis buffer, and analyzed for
co-immunoprecipitating proteins by immunoblotting with a
p85
-specific mouse monoclonal antibody (UBI), Ha-Ras mouse
monoclonal (3E4-146, Quality Biotech), or B-Raf goat polyclonal
antibody (SC166, Santa Cruz Biotechnology). Peroxidase-labeled
secondary antibodies (anti-mouse or goat, Pierce) were used with
development by ECL (Pierce) using the manufacturer's protocol.
In Vitro Lipid and Protein Kinase Assays--
PI3-kinase lipid
kinase activity was measured using the in vitro assay
described by Ref. 34. Anti-p85 immune complexes were prepared from 300 µg of whole cell lysates or from 150 µg (each) of S100 and P100
fractions and incubated with [
-32P]ATP (10 µCi/reaction, ICN) and phosphatidylinositol (10 µg/reaction, Sigma)
for 10 min. The phospholipids were extracted in
CHCl3:CH3OH (1:1) and separated by thin layer
chromatography on potassium oxalate-coated silica plates (Analtech)
developed in propanol:2 M acetic acid (65:35). Radioactive
32P-phosphatidylinositol-3 phosphate was detected by
autoradiography, and the film images were scanned and quantified using
the program ImageQuant (Molecular Dynamics). The radioactive
phosphatidylinositol-3 phosphate product was identified on the basis of
co-migration with an unlabeled phosphatidylinositol 4-phosphate
standard visualized by iodine staining. Duplicate p85
immunoprecipitates were resolved by SDS-PAGE, and p85 was detected by
immunoblotting and quantified by scanning to determine the amounts of
p85 captured in the immunoprecipitates.
The activity of the endogenous B-Raf kinase was measured with a coupled
in vitro kinase assay (37). B-Raf immune complexes from
whole cell lysates (300 µg) were collected on protein A-conjugated agarose beads and incubated with nonradioactive ATP and purified recombinant MEK protein (100 µg/ml; provided by Dr. Lee Graves, Chapel Hill, NC). After 10 min, recombinant ERK2 (250 µg/ml; provided by Dr. Lee Graves) was added, and after another 10 min, 250 µg/ml myelin basic protein (Fisher) and [
-32P]ATP (5 µCi/assay) were added. The reactions were finally terminated 10 min
later by the addition of 100 mM EDTA; reaction products were spotted onto P-81 phosphocellulose paper (Whatman) and washed in
10% phosphoric acid, and incorporation of 32P into the
precipitated myelin basic protein was quantitated by scintillation counting.
Rac GTP/GDP Binding--
At 4 days post-transfection, PC12 cells
co-expressing HA-tagged Rac1 (7 µg DNA) and either Ha-Ras61L or
Ext61L were incubated overnight in medium containing 1% dialyzed calf
serum. Cells were then radiolabeled with 0.5-1 mCi/ml 32P
inorganic phosphate (NEN Life Science Products) for 4 h in
phosphate-free medium containing 1% dialyzed calf serum. Cells
were lysed; samples were precleared of Ha-Ras by immunoprecipitation
with antibody 3E4-146, and then the HA-Rac1 proteins were isolated by
immunoprecipitation, as described above, using an anti-HA antibody
(Babco, MMS-101R). GTP and GDP were separated by thin layer
chromatography (28) with the following important changes. Cells were
lysed in a buffer containing 50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS,
20 µg/ml aprotinin, 1 mM EGTA, 1 mM
Na3VO4. For more quantitative elution of
Rac-bound nucleotides it was necessary to heat the samples to 70 °C
for 10 min in 20 µl of buffer containing 20 mM Tris-HCl
(pH 7.4), 2 mM EDTA, 2% (w/v) SDS, 2 mM GDP,
and 2 mM GTP.
 |
RESULTS |
Ext61L Induces Exaggerated Morphologic Changes in PC12
Cells--
PC12 cells respond to the expression of activated Ras
proteins by the cessation of growth and the extension of neurites
(38-40). This differentiation process is characterized by
rearrangements of the actin cytoskeleton at the plasma membrane,
leading to the formation of small lamellipodia, growth cones, and the
subsequent extension of axon-like processes (41). Previously, the
Ext61L protein had been shown to cause morphologic changes in PC12
cells that were easily distinguishable from those caused by Ha-Ras61L, including an increased number and accelerated rate of outgrowth of
neuron- like structures and large lamellipodia with ruffles (28). This
exaggerated response suggested that the Ext61L protein produced
differentiation signals that were either exceptionally strong or that
utilized different signaling pathways than Ha-Ras with a native C
terminus and lipid modifications.
To examine if the dramatic external morphological changes caused by
Ext61L were accompanied by exaggerated changes in the actin filaments
that are normally rearranged during neurite outgrowth, the distribution
of filamentous actin was examined by immunofluorescence using
rhodamine-conjugated phalloidin. Control cells treated with nerve
growth factor formed actin-rich neurites after 4 days, with growth
cones visible at the ends of the extending neurites (Fig. 1, NGF panel). Cell bodies
displayed little flattening and low levels of filamentous actin.
Similar changes in the actin cytoskeleton accompanied differentiation
triggered by expressing Ha-Ras61L (Fig. 1, 61L panel).
Expression of Ext61L led to more extensive changes in actin structures.
Neurites, often longer than 100 µm, developed within 24 h of
transfection and at 4 days post-transfection cells exhibited marked
somal flattening and very long, thin, actin-rich neurites displaying
extensive branching (Fig. 1, Ext61L 50 µm panel). At higher magnification, cortical actin and
actin-containing microspikes could be seen in the large membrane
ruffles, with short perpendicular filament bundles leading to the edge
of the cells and truncated and poorly organized actin filaments
throughout the cell interior (Fig. 1, Ext61L 25 µm
panel). Thus the morphological changes caused by Ext61L
involved actin cytoskeletal changes. More importantly, the exaggerated
features of the changes caused by Ext61L indicated that Ext61L,
although identical to Ha-Ras in its switch I (designated effector
domain) and switch II regions, affected the actin cytoskeleton in a
distinct way.

View larger version (95K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of Ext61L on the actin cytoskeleton of
PC12 cells. Fluorescence of rhodamine-conjugated phalloidin was
used to visualize polymerized actin in PC12 cells expressing Ha-Ras61L
(61L) or Ext61L or treated with 50 ng/ml nerve growth factor for 4 days. Panels labeled PC12, nerve growth factor, or 61L are at the same
magnification as the Ext61L panel with the 50-µm scale bar. The
arrows indicate growth cones; arrowheads the
microspikes along outgrowths; the open arrowhead points
toward cortical actin underlying the plasma membrane; and an
asterisk is placed over a broad ruffle on the flattened cell
body. These fluorescent images were typical of cells expressing
these constructs, and similar results were recorded in four separate
experiments. The scale bar for the higher magnification panel of Ext61L
is 25 µm.
|
|
Prevention of Neurite Outgrowth by Ext61L Requires Elevated Amounts
of Inhibitory Rac1(N17)--
Many aspects of actin cytoskeleton
regulation, in both fibroblasts and PC12 cells, are controlled by the
Rho family of GTPases, which include several Rho, Rac, and Cdc42
proteins (42-44). Each of these proteins has also been reported to
function downstream of Ha-Ras and to contribute to the effects of
Ha-Ras on the actin cytoskeleton (45-47). The Rac proteins in
particular appear to be involved in remodeling of the actin
cytoskeleton during formation of ruffles or lamellipodia. The large
flattened and ruffled cell bodies of the cells expressing Ext61L
suggested that a pathway involving Rac proteins might be strongly
activated. Thus more direct studies were undertaken to determine if
these Rho family proteins were involved in the unusual changes in the
actin cytoskeleton caused by Ext61L.
In PC12 cells, neurite extension has been shown to be reduced when the
activity of Rac1, Cdc42, or PAK1 kinase is reduced or when RhoA is
activated (31, 32, 48) (see Fig. 6). PC12 cells were therefore
co-transfected with DNAs encoding either Ha-Ras61L or Ext61L and DNAs
encoding Cdc42(17N), Rac1(17N), PAK-1-(165-205), and RhoA(14V). The
length, number and morphology of the resulting neurites were examined 2 days later by phase contrast microscopy, when neurites could still be
accurately assigned to a particular cell body. Pictures of
differentiated cells were taken on day 4 when the morphological changes
caused by Ext61L were most distinct. Because a substantial amount of
Ext61L protein is cytosolic, the amounts of the Ras DNAs were carefully
titrated to result in expression of equal amounts of each Ras protein
in the membranes (P100 fraction) of the PC12 cells (see Fig.
4C for example). These amounts of DNA induced ~60% of the
cells to extend outgrowths that at 2 days were at least 100 µm in
length (twice the diameter of an untransfected cell). Co-expression of
RhoA(14V), Cdc42(17N), or PAK-1-(165-205) reduced the number
of cells with outgrowths of this length
to ~30% for Ha-Ras61L and ~26% for Ext61L (Table
I). This indicated that Ext61L
utilized RhoA, Cdc42, and PAK activities to produce neurite outgrowths.
In addition, the sensitivity of these pathways to inhibition was
roughly similar in cells expressing Ha-Ras61L or Ext61L.
In contrast to the sensitivity of Ext61L-triggered outgrowths to the
inhibitory Rho, Cdc42, and PAK proteins, the ability of an inhibitory
Rac(N17) to decrease responses of Ext61L-expressing cells was much more
limited. At an amount of Rac(N17) expression that strongly suppressed
formation of neurites by Ha-Ras61L (Fig. 2, inset), cells expressing
Ext61L showed no decrease in the rate of neurite elongation or in the
number of cells with neurite outgrowths (Table I and Fig.
2B). However, the neurites on cells co-expressing Ext61L and
Rac(17N) did display a subtle change in morphology; processes were
smooth, had only a single growth cone and no branching, and showed
fewer ruffles and lamellipodia (Fig. 2B). 3-Fold more Rac(17N) DNA was needed to cause clear inhibition of outgrowths from
cells co-expressing Ext61L (Fig. 2C). This DNA concentration caused production of ~3-fold more Rac(17N) protein (data not shown). To verify that this depressed outgrowth response was not caused by
toxicity from a high amount of Rac(17N), the amount of Rac(17N) DNA was
held constant and the amount of Ext61L DNA was decreased 5-fold. This
protocol also inhibited neurite outgrowth. Thus both the previous
observation of numerous lamellipodia and this poor response of
Ext61L-induced neurites to Rac(17N) suggested that the Rac proteins
might be hyperactivated in the cells expressing Ext61L.

View larger version (94K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of Rac1(17N) on formation of
Ext61L-induced outgrowths. PC12 cells were co-transfected with
plasmids encoding Ext61L (a, b, c, and
f) or Ha-Ras61L (d and e) and the
indicated amounts of Myc-Rac1(N17) (b, c, and
e) or 4-Ptase (f). After 4 days cells were imaged
using phase-contrast microscopy. Expression of Rac(17N) did not alter
the expression of the Ras proteins. The inset is of an
anti-Myc immunoblot showing that similar amounts of Myc-Rac(N17)
protein were expressed in cells in b (Ext61L) and
e (61L).
|
|
Ext61L Induces a Sustained Increase in GTP-bound Rac1--
The
possibility of excessive stimulation of the Rac pathway was examined by
comparing GTP binding of Rac in cells expressing Ext61L or Ha-Ras61L.
PC12 cells were transfected with either Ha-Ras61L or Ext61L, and, to
obtain sufficient amounts of Rac for this direct analysis, an
epitope-tagged, cellular form of Rac1 (HA-Rac1). This cellular form of
Rac would replicate the sensitivity of the endogenous Rac proteins to
Ras-mediated effects on guanine nucleotide exchange factors and
GTPase-activating proteins. HA-Rac1 caused no effects on formation of
outgrowths when expressed in concert with Ras proteins (data not
shown). At 4 days post-transfection, when neurites in both types of
Ras-transfected cells were well established, the cells were labeled
with 32Pi. To prevent the co-expressed Ras
proteins from contributing to the nucleotides to be detected, the
Ha-Ras proteins were first removed by immunoprecipitation, then anti-HA
immunoprecipitates were formed, and the radioactive nucleotides bound
to the HA-tagged Rac1 were analyzed. Anti-Ha-Ras immunoblots performed
on HA-immunoprecipitates prepared from replicate, nonradioactive plates
confirmed that no Ha-Ras was present in the Rac1 samples (data not
shown). In undifferentiated cells in which only HA-Rac1 had been
introduced, the basal amount of GTP-bound HA-Rac1 averaged 8 ± 2% (Fig. 3). Co-expression of Ha-Ras61L
caused a modest increase in Rac GTP binding, 1.3-fold, to 10 ± 0.7%. This increase in Rac GTP binding was similar to the level
attained during the transient stimulation of Rac GTP binding by PDGF
that had been reported previously (49). Increasing the amount of
Ha-Ras61L DNA transfected did not further increase HA-Rac1 GTP binding
(data not shown), suggesting that with Ha-Ras61L, cellular regulatory
mechanisms were able to limit Rac activation to levels only slightly
above those in control cells. However, Ext61L stimulated HA-Rac1 more
strongly, resulting in a 2.1-fold increase in GTP-bound HA-Rac1
(17 ± 0.8%) over the Mock-transfected cells and a 1.7-fold
increase over that in the Ha-Ras61L-transfected cells. Thus even after
4 days, expression of the Ext61L protein continued to support increased
GTP binding to Rac1. This sustained activation of Rac quite likely
contributes to the formation of the large lamellipodia and other
dramatic changes in the PC12 cell actin cytoskeleton.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 3.
Identification of nucleotide bound to HA-Rac1
proteins. PC12 cells were transfected with HA-Rac1 and either
Ha-Ras61L or Ext61L, and 4 days later they were incubated with
32Pi for 4 h. The HA-Rac1 protein was
immunoprecipitated, and bound nucleotides were eluted, separated by
thin-layer chromatography, and detected by autoradiography. The amounts
of GTP were quantified by phosphoimager analysis. The averages and
S.D., from four independent experiments, of the portion of HA-Rac1 that
bound GTP were 8 ± 2% in cells without Ras (lane 1),
10 ± 0.7% in cells co-expressing Ha-Ras61L (lane 2),
and 17 ± 0.8% in cells expressing Ext61L (lane 3). An
immunoblot (lower panel) of replicate plates verified that
similar amounts of the HA-Rac1 were present in all
immunoprecipitates.
|
|
Ext61L-mediated Neurite Outgrowth Requires PI3-Kinase
Activity--
There are several guanine nucleotide exchange factors
that have been reported to be able to stimulate Rac GTP binding (50, 51), but it is not clear which of these might be the relevant guanine
nucleotide exchange factor for neurite outgrowth in PC12 cells.
Importantly, each of these guanine nucleotide exchange factors contain
a pleckstrin homology domain. Recent reports imply that binding of
phosphoinositides (PtdIns-3,4-P2 or
PtdIns-3,4,5-P3) to the pleckstrin homology domain
may influence membrane binding or activity of some guanine nucleotide
exchange factors (45). To learn if PtdIns-3,4-P2 was needed
for production of the unusual morphology caused by Ext61L, expression
of a Type I 4-Ptase was used to deplete this second messenger by
removing the phosphate at the 4 position of PtdIns-3,4-P2,
producing the inactive PtdIns-3-P (52, 53). Although 4-PTase did
not, on its own, cause differentiation of the PC12 cells (data not
shown), co-expression of 4-Ptase with Ext61L caused a moderate
reduction in the number of cells that had outgrowths. This reduction
was substantial, given that 4-Ptase does not hydrolyze
PtdIns-3,4,5-P3, so this other active phosphoinositide was
still present. More notably, in those cells that did have outgrowths,
the cell bodies no longer displayed the distinctive lamellipodia,
multiple neurites, or branching that characterize Ext61L-mediated
differentiation (Fig. 2F). Thus, by limiting
PtdIns-3,4-P2 accumulation the exaggerated morphology
caused by Ext61L was suppressed and came to resemble more closely the
response caused by Ha-Ras61L. This result indicated that
phosphoinositides play a role in the abnormal outgrowths caused by Ext61L.
One likely source for these phosphoinositides could certainly be a
PI3-kinase, as p110
or p110
isoforms of PI3-kinase catalytic subunits of this enzyme have been identified as Ras effector proteins (54). However, in T lymphocytes and human neutrophils, a second, PI3-kinase-independent pathway linking Ras to Rac activation has been
reported (55, 56). Inhibitors of PI3-kinase were used to explore if a
PI3-kinase supplied the phosphoinositols used for Ext61L-induced
process formation. The PI3-kinase inhibitor LY294002 effectively
decreased neurite formation induced by expression of Ext61L (Table I).
Similar results were obtained with wortmannin (data not shown). In
addition, co-expression of
p85, a putative dominant negative
deletion mutant of the regulatory p85 subunit of PI3-kinase, also
effectively suppressed Ext61L-mediated neurite formation (data not
shown). These data indicated that neurite outgrowth induced by Ext61L
was PI3-kinase-dependent. From all of these results it thus
appeared that Ext61L strongly stimulated production of
phosphoinositides that led to activation of Rac GTP binding.
Ext61L Activates PI3-Kinase More Strongly than Does
Ha-Ras61L--
A reasonable hypothesis for how Ext61L might enhance
production of 3'-phosphoinositides was through increased binding to or activation of the p110 (
or
) catalytic subunits of PI3-kinase. To test this possibility, the activation states of the endogenous PI3-kinase in PC12 cells expressing Ext61L or Ha-Ras61L were compared. Although experiments to isolate p85 or p110 proteins in an Ha-Ras immunoprecipitate were attempted, the small amount of p85 or p110 that
could be captured proved to be insufficient to clearly distinguish PI3-kinase subunits from nonspecific proteins by immunoblot detection. Therefore, immunoprecipitation of p85 (using antibody that allowed co-capture of p110
/p110
subunits) was used to isolate PI3-kinase and obtain a comprehensive picture of the activity of total p110, whether associated with Ha-Ras or not. In cells expressing Ext61L, the
total kinase activity of p110 was ~2-fold (1.76 ± 0.5, n = 3) higher than in cells expressing equivalent
amounts of Ha-Ras61L (Fig.
4A). A similar ~2-fold
higher total PI3-kinase activity was also found in cells assayed at
24 h after transfection (data not shown). To test if this increase
in p110 activity was dependent upon GTP binding of the Ext61L protein,
a largely GDP-bound cellular version, ExtWT, was examined (28).
Total p110 PI3-kinase activity in cells expressing ExtWT was roughly
one-third (0.3 ± 0.01, n = 3) of that in cells
expressing Ext61L (Fig. 4A), indicating that Ext61L GTP
binding contributed to the activation of PI3-kinase. However, only
membrane-bound Ras is thought to be competent for PI3-kinase
activation, and unlike fully membrane-bound Ha-Ras61L with the native
lipid modifications, there is a substantial amount of cytosolic,
GTP-bound Ext61L (28; see Fig. 4C). Therefore a second set
of assays was performed to learn if the increase in total PI3-kinase
activity resulted from enhanced activation in primarily one location,
or in both cytosolic and membrane fractions. In cells expressing
Ha-Ras61L, the majority of the PI3-kinase activity was found in the
cytosolic fraction (70 ± 4%; Fig. 4B). In contrast,
in cells expressing Ext61L, more than three-fourths of the PI3-kinase
activity was membrane-associated (82 ± 6%; Fig. 4B).
Cytosolic PI3-kinase activity was definitely not enhanced and instead
appeared to be diminished, whereas the activity of PI3-kinase in the
membrane fraction was elevated ~2-fold compared with its activity in
membranes from Ha-Ras61L-expressing cells. Thus the increase in total
PI3-kinase activity caused by expression of Ext61L resulted primarily
from increased amount or activity of PI3-kinase that was associated
with membranes. The increase in membrane-located PI3-kinase activity
could therefore produce 3'-phosphoinositides that might lead to
activation of Rac and other cytoskeletal proteins that contribute to
actin rearrangements during differentiation of PC12 cells.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 4.
PI3-kinase is more active in cells expressing
Ext61L. A, whole cell lysates (300 µg of total
protein) prepared from PC12 cells expressing cellular Ha-Ras
(WT), the cellular form of ExtRas (ExtWT),
Ha-Ras61L (61L), or Ext61L were immunoprecipitated
using an anti-p85 polyclonal antibody. PI3-kinase activity associated
with the immunoprecipitates was measured with an in vitro
lipid kinase assay using phosphatidylinositol as substrate. The
phosphorylated products of the reactions were resolved by TLC,
visualized by autoradiography, and quantified by phosphoimager
analysis. The arrow indicates the radioactive
32P-phosphatidylinositol-3 phosphate
(32P-PtIns-P). B, cytosolic
(S) and membrane (P) fractions were prepared 4 days after transfection from PC12 cells expressing Ha-Ras61L or Ext61L.
Anti-p85 immunoprecipitates were formed from 150 µg of protein from
each fraction, and activity of the captured PI3-kinase was assessed
with an in vitro lipid kinase assay. The phosphorylated
products were resolved by TLC, visualized by autoradiography, and
quantitated by phosphoimager analysis. Ha-Ras and p85 immunoblots of
duplicate samples confirmed that equivalent amounts of Ha-Ras and p85
protein were present in the P fractions of the precipitates. An average
30 ± 4% of the total PI3-kinase activity in PC12 cells
expressing Ha-Ras61L was membrane-associated, whereas 82 ± 6% of
the total PI3-kinase activity in cells expressing Ext61L was
membrane-associated. These values represent the average and S.D. of
four independent experiments. C, cytosolic (S)
and particulate (P) fractions (150 µg of total protein)
were prepared from PC12 cells expressing Ha-Ras61L or Ext61L.
PI3-kinase immunoprecipitates were formed using an anti-p85 polyclonal
antibody and resolved by SDS-PAGE, and p85 (upper panel) or
Ha-Ras (middle panel) was detected by immunoblotting.
Separate aliquots of each fraction were taken before
immunoprecipitation; acetone precipitated and amounts of Ha-Ras
proteins present in the fractions were detected by immunoblotting
(lower panel). IP denotes immunoprecipitation,
and IB denotes immunoblot.
|
|
To understand more of how Ext61L might be enhancing PI3-kinase
activity, the interaction between the p85-p110 PI3-kinase complex and
Ras proteins was examined. A modest amount of Ha-Ras61L could be
detected in p85 immunoprecipitates prepared from membrane fractions (Fig. 4C, middle panel). Because Ha-Ras61L is fully
membrane-bound, no protein was detected in the soluble fraction. In
cells expressing the Ext61L protein, which is ~60% cytoplasmic, a
small amount of Ext61L interacted with the p85 in the cytosolic
fraction. However, the amount of Ext61L in the p85 immunoprecipitate
from the membrane fraction was 6-10-fold greater than the amount of
Ha-Ras61L that bound to p85 in the membrane sample (Fig. 4C,
middle panel). This increase in PI3-kinase-Ext61L interaction
occurred despite the nearly equal amounts of Ext61L and Ha-Ras61L
proteins that were available in the P100 samples (Fig. 4C, bottom
panel). The enhanced interaction did not appear to reflect
differential isolation of Ext61L in DRMs that might have been present
in the p85 immunoprecipitates, as warming the Triton X-100-containing,
resuspended P100 fractions for 2 min at 37 °C to solubilize DRMs and
release proteins prior to formation of the immunoprecipitates (35) did
not diminish the enhanced amount of Ext61L found in the p85 sample
(data not shown). Thus, much more Ext61L than Ha-Ras61L interacted with PI3-kinase, and increased binding was, as with the lipid kinase activity, predominant in the membrane fraction. The sum of all these
results suggested that the unusual structure or lipidation of the C
terminus of Ext61L, in the absence of any mutation in the effector
domain, caused hyperactivation of a PI3-kinase/Rac pathway that
contributed to an exaggerated and abnormal program of neuronal
differentiation in PC12 cells.
Ext61L Binding to B-Raf Is Increased but Activation Is
Decreased--
However, the Rac pathway is not solely responsible for
differentiation. Cooperation from other pathways is also required for Ras-mediated PC12 cell differentiation. To learn if the novel structure
of Ext61L allowed it to activate all Ras effector proteins, or if it
selectively stimulated PI3-kinase, the effect of Ext61L on the activity
of the B-Raf/MEK/ERK pathway was examined. The compound PD98059 was
used to inhibit the activation of MEK (57) and phosphorylation of its
targets, ERK1 and ERK2, monitored by immunoblotting. Treatment of PC12
cells with PD98059 almost completely blocked activation of ERKs caused
by expression of either Ext61L or Ha-Ras61L (data not shown). In
addition, PD98059 blocked Ext61L-induced differentiation of PC12 cells
as effectively as it blocked Ha-Ras61L-induced outgrowths (Table I).
Thus differentiation induced by Ext61L required MEK activity and
appeared to be as sensitive to loss of its activity as Ha-Ras61L.
To more directly assess interaction of Ext61L and an actual effector,
endogenous B-Raf was isolated by immunoprecipitation and assayed for
the co-immunoprecipitation of Ext61L by immunoblotting. B-Raf
immunoprecipitates contained 6-10-fold more Ext61L than Ha-Ras61L and
these complexes were found specifically in membrane-containing fractions (Fig. 5A). A similar
dramatic increase in B-Raf-Ext61L complex formation was observed when a
cDNA was used to overexpress B-Raf in PC12 cells co-expressing
Ext61L or Ha-Ras61L (data not shown). Thus B-Raf could bind much more
Ext61L than Ha-Ras61L, although both proteins bound GTP to the same
extent (28). This result was similar to what had been observed for
interaction between PI3-kinase and Ext61L and indicated that both
effectors formed complexes with Ext61L remarkably well.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 5.
Ha-Ras61L expression causes greater
activation of B-Raf than Ext61L. A, cytosolic
(S) and particulate (P) fractions (150 µg of
total protein) were prepared from PC12 cells expressing Ha-Ras61L
(61L)or Ext61L proteins. The endogenous B-Raf was
immunoprecipitated and resolved by SDS-PAGE, and any associated Ha-Ras
protein was detected with Ha-Ras antibody. Separate aliquots of each
fraction were taken before immunoprecipitation and acetone
precipitated, and amounts of Ha-Ras proteins present in the fractions
were detected by immunoblotting. IP denotes
immunoprecipitation, and IB denotes immunoblot.
B, cytosolic (S) and particulate (P)
fractions (150 µg of protein from each fraction) were prepared from
PC12 cells transfected with a plasmid encoding p95 B-Raf along with
either Ha-Ras61L or Ext61L DNAs. Four days later the cells were lysed;
Ha-Ras protein immunoprecipitates were formed and resolved by SDS-PAGE,
and any associated B-Raf protein was detected with B-Raf antibody.
C, whole cell lysates (300 µg of total protein) were
prepared 4 days post-transfection from PC12 cells expressing Ha-Ras61L
or Ext61L. B-Raf immunoprecipitates were formed, and coupled immune
complex kinase assays were performed utilizing recombinant Mek1 and
ERK2 proteins and [ -32P]ATP to ultimately label myelin
basic protein as a substrate. The radioactivity incorporated into
myelin basic protein was quantified by scintillation counting. B-Raf
activity in mock-transfected cells was set to 1.00. In cells expressing
Ha-Ras61L, B-Raf activity averaged 3.95 ± 1.4-fold higher; in
cells expressing Ext61L, B-Raf activity averaged 2.28 ± 0.58-fold
higher than mock-transfected cells. These values represent the average
and S.D. of four independent experiments. A representative B-Raf
activity in Ha-Ras61L transfected cells was 16,014 cpm. D,
whole cell lysates (300 µg of total protein) were prepared from PC12
cells that were mock-transfected (lane 1) or cells
expressing Ha-Ras61L (61L) (lane 2) or Ext61L
(lane 3) proteins 4 days after transfection and displayed by
SDS-PAGE. ERK1 and ERK2 proteins were detected by immunoblotting. ERK
activation is indicated by the amount of phosphorylated ERK
(P-ERK). IB denotes immunoblot.
|
|
Overexpression of B-Raf was then used to ask the reciprocal question of
whether the nonfarnesylated Ext61L could bind more B-Raf than could
fully lipid-modified Ha-Ras61L. Ras immunoprecipitates were prepared
and probed with B-Raf antibodies. In Ha-Ras61L immunoprecipitates from
membrane fractions, detectable amounts of the co-expressed exogenous
B-Raf protein were observed. However, much more B-Raf was present in
Ext61L immunoprecipitates from membrane fractions (Fig. 5B),
although equivalent amounts of membrane-associated Ha-Ras61L and Ext61L
were available (data not shown). This result showed that Ext61L, even
though it lacked the farnesyl moiety, could still bind B-Raf.
However, full activation of Raf kinase activity requires much more than
simple binding between the designated Ras effector domain and the Ras
binding domain of Raf (21). To determine whether increased association
between B-Raf and Ext61L was translated into increased activation of
B-Raf, endogenous B-Raf was captured by immunoprecipitation and its
kinase activity measured using an in vitro assay. In cells
expressing Ha-Ras61L, B-Raf activity was stimulated 4-fold over basal
levels (Fig. 5C). In contrast, B-Raf activity in cells
expressing Ext61L, although elevated (2-fold), was one-half that of the
B-Raf activity in Ha-Ras61L-expressing cells (Fig. 5C).
Similar results (~4-fold increase in B-Raf activity with Ha-Ras61L
but only ~2-fold increase with Ext61L) were found in assays performed
1 day after transfection of the cells (data not shown). Thus, despite
the obvious increase in binding between B-Raf and Ext61L, this
interaction produced little B-Raf activation.
Because ERK1 and ERK2 play key roles in Ras signaling and can further
indicate B-Raf activity, Ext61L effects on ERK phosphorylation in the
intact cell were examined. Although Ha-Ras61L expression caused robust
phosphorylation of both ERK1 and ERK2, Ext61L expression produced a
noticeably smaller increase (Fig. 5D). The poor ERK response
suggests either that Ext61L does not efficiently activate the
B-Raf/MEK/
ERK pathway within cells or that other effects of Ext61L down-regulate
this pathway. The poor stimulation of B-Raf activity by Ext61L was very
different from its hyperactivation of PI3-kinase activity and
demonstrates that effects of Ext61L vary between effectors, leading to
unbalanced use that may further contribute to its unusual activity.
 |
DISCUSSION |
Activation of a PI3-Kinase Pathway--
Ext61L appears to define a
new class of PI3-kinase selective Ha-Ras protein in which C-terminal
alterations in Ha-Ras can lead to an enhancement of the activity of
this effector protein and its targets (Fig.
6). The data presented here also provide support for a model in which binding of effector proteins to Ras-GTP, in addition to a required and nondiscriminating interaction with the
classical Ras effector domain, is influenced by the lipidated C-terminal domain.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 6.
Schematic signaling pathways of Ext61L in
PC12 cell neurite outgrowth. Several of the Ras effectors proteins
and some of the pathways through which they are proposed to contribute
to neurite outgrowth are depicted. Not all effectors, proposed
pathways, or connections are shown. The hierarchy of interactions
between the Rho family GTPases reported in fibroblasts may not occur in
neural cells. The octagonal "stop signs" indicate positions where
pathways were inhibited by the following compounds or proteins:
1, PD98059 inhibitor of MEK; 2, LY294002
inhibitor of PI3-kinase; 3, Rac(17N); 4, PAK1-(165-205); 5, Cdc42(17N); 6, RhoA(14V).
|
|
The hyperactivation of a PI3-kinase/Rac pathway found in these studies
is likely to play a key role in the prominent, actin-based morphological changes observed in PC12 cells that express Ext61L. Expression of either cellular (wild type) forms or the activated Myc-RhoA(19N), Myc-Rac1(12V), or Myc-Cdc42(12V) proteins failed to
promote PC12 neurite
formation,2 as had
been reported previously (31, 32). Preliminary studies also indicated
that co-expression of Ha-Ras61L with a constitutively active form of
PI3-kinase (p110-CAAX) could produce many, but not all, of
the morphological events seen with Ext61L.2 Thus
multiple pathways must participate cooperatively to produce the coupled
and complex program of cessation of cell cycling and neurite outgrowth
that produce differentiation of PC12 cells. Future efforts will require
determining how other effector pathways, such as Cdc42 and Rho,
contribute to the unusual cytoskeletal changes caused by Ext61L.
There are two ways that seem most likely to explain how Ext61L may
enhance PI3-kinase signaling. Ext61L may be distributed in the plasma
membrane in a location that favors PI3-kinase activity once the enzyme
is bound to Ha-Ras through normal means. This model emphasizes the
traditional role of the C terminus in lipid bilayer interactions.
However, the multiple lysines and lack of a farnesyl group in Ext61L
may also alter the conformation of the C terminus, particularly when it
is in contact with the bilayer. These unique C-terminal features of
Ext61L may allow it to bind PI3-kinase more avidly. This model focuses
on a new, more direct role for the C terminus in protein interaction
that is separate from, but could easily cooperate with, its use in
membrane binding.
Contribution of Membrane Binding to Ext61L Function--
Ext61L
differs from the many other C-terminal mutants of Ha-Ras. Most
C-terminal alterations have caused mislocalization to internal
membranes (17) or prevented membrane binding entirely. Such C-terminal
mutant proteins display poor biological activity. The results presented
here indicate that the alterations in the lipidation and C terminus of
Ext61L, rather than being detrimental to function, actually enhance the
ability of the protein to cause differentiation of PC12 cells, as shown
by the multiple and branched neurite outgrowths and the large
lamellipodia. A distinctive aspect of Ext61L is the large portion
(60%) of the protein that is present in the cytosol. This cytoplasmic
protein lacks lipids but retains the six additional lysines and, having
the activating 61L mutation, is GTP-bound (28). However, neither
PI3-kinase nor B-Raf interacts well with this protein (see Figs.
4C and 5A). This result indicates that the
lysines in the Ext61L protein cannot by themselves be responsible for
the enhanced effector binding and that soluble Ext61L likely
contributes little to the signals produced by Ext61L. More importantly,
these data suggest that these two effectors can discriminate between
cytosolic and membrane-bound Ext61L, even when this Ha-Ras protein is
in a GTP-bound form. The results therefore indicate that effector
binding can be influenced by more than the classical effector domain or
activation state of Ha-Ras and point out that lipid modification and/or
membrane binding of the C-terminal domain are crucial for this regulation.
Within the plasma membrane, Ha-Ras may further partition into
glycolipid-enriched membrane subdomains ("rafts"). It is suspected that both of the lipids attached to Ha-Ras play a significant role in
this lipid bilayer distribution, but their individual contributions
remain unresolved (58-60). The presence of an isoprenoid is reported
to inhibit such partitioning, whereas palmitoylation encourages
targeting to rafts. The effect of the combination of palmitates and
lysine residues in Ext61L is not known. Our current co-immunoprecipitation results suggest that enhanced interactions of
Ext61L and PI3-kinase can still be detected even under conditions in
which rafts (DRMs) are solubilized (35). We have previously shown that
Ext61L is successfully targeted to the plasma membrane (28), but
additional studies will be needed to learn if the novel lipidation of
Ext61L causes it to partition between rafts and the general lipid
bilayer differently from fully lipidated Ha-Ras. An abnormal
distribution might contribute to Ext61L's strong activation of
PI3-kinase by either improving access of p110 to Ext61L-GTP or by
enhanced proximity of Ras-bound p110 to its phosphatidylinositol
substrates (61). In either case, the increased production of such lipid
products will activate a variety of pleckstrin homology
domain-containing proteins that can regulate the actin cytoskeleton, as
shown here (45, 62), and others, such as members of the Akt/protein
kinase B family that stimulate pathways that regulate cell survival
(62-64). The dramatic increase in co-immunoprecipitation of Ext61L by
both PI3-kinase and B-Raf clearly indicates that the novel C-terminal structure of Ext61L has a substantial influence on interactions with
these two effectors. These data are compatible with a mechanism involving change in access of effectors to Ras. However, although the
amount of Ext61L that interacted with PI3-kinase was >5-fold more than
with Ha-Ras61L, a similar increase was also seen with B-Raf and was
thus nonselective and cannot explain the differential activation of
these effectors. Whereas the current studies do not resolve these
issues, the use of Ext61L should facilitate characterization of how
membrane distribution, engagement, and activation of these two
effectors are interrelated.
Involvement of the Ext61L C Terminus in Effector
Interaction--
The additional argument can be made that changes in
Ext61L membrane binding simply augment more direct changes in the
interaction between Ext61L and p110 or B-Raf. Ext61L is exceptional in
that it unbalances effector utilization without introducing mutations in the effector domain or affecting GTP binding. Previous studies seeking to correlate binding of individual Ras effectors with biological activity have exploited Ras proteins with mutations in the
classical effector domain (residues 32-40). These individual point
mutations in the effector domain, although remarkably able to prevent
binding of the targeted effector, also weaken the activation of the
remaining effectors (65), and the cumulative biological result is
impaired Ras function. The retention of effector domain structure in
Ext61L can be inferred by the sensitivity of Ext61L function to such
mutations in the classical effector domain; a Ext61L(Y40C) mutant no
longer causes neurite
outgrowth.3 In
contrast to the effector domain mutants, at least 2 cellular responses
mediated by Ext61L remain robust. The transforming activity of Ext61L
in NIH 3T3 cells is equivalent to that of Ha-Ras61L (28). In PC12 cells
Ext61L is exceptionally potent, and even the cellular version, ExtWT,
can cause outgrowth of neurites (28). However, ExtWT activates
PI3-kinase much less well than Ext61L in PC12 cells and shows an
appropriate lack of transforming activity in NIH 3T3 cells. This
indicates that although the C-terminal extension imparts several novel
properties to Ext61L, GTP binding enhances Ext61L signaling and remains
an important component of the signaling mechanism. The current findings
thus indicate that Ext61L unbalances effector utilization and activates
biological signaling through a unique mechanism that differs from that
caused by the effector domain mutants.
Because the classical effector domain of Ext61L appears unchanged, the
unique C-terminal structure of Ext61L appears to be the source of
increased interaction between Ext61L and the two effectors PI3-kinase
and B-Raf. As noted above, the multiple lysines cannot be solely
responsible for this enhanced effector binding, as they are present on
the cytosolic protein that binds both B-Raf and PI3-kinase poorly,
although they are likely to contribute to binding in the membrane form
of Ext61L. These results indicate that enhanced interaction with
PI3-kinase requires juxtaposition of the C terminus of Ext61L to the
membrane. This raises the possibility that when the C terminus of
Ext61L (and perhaps that of native Ha-Ras as well) interacts with the
lipid bilayer, this domain might adopt a definable tertiary structure
important for effector interactions. The possibility of a nonrandom
structure of the membrane binding domain of Ha-Ras has not been
examined previously. This lack of attention comes, in part, because
although the three-dimensional structures of several forms of Ha-Ras
have been solved, these structures are missing the last ~20 amino
acids and provide no information on the placement of the C terminus or
its lipids. Such information may now be obtainable using the recently
reported success of bioorganic synthesis of lipidated Ha-Ras proteins
(66). Importantly, the data from Ext61L suggest that at least two
effector proteins may sense C-terminal conformation. This model further implies that lipid modifications of Ha-Ras might play a direct role in
imposing or contributing to this structure. Such a prospect would
broaden the job description of lipids beyond targeting and partitioning
of Ha-Ras in the membrane. Our work with Ext61L and a second,
nonfarnesylated Ha-Ras with C-terminal palmitates show that palmitates
can physically support partial Ha-Ras membrane binding, despite their
dynamic turnover in the cell (28, 67). Those results support the
possibility that in native Ha-Ras the farnesyl group could be free for
roles besides membrane tethering.
Is a Farnesyl Group Involved in Effector Activation?--
The
exceptional activation of PI3-kinase by Ext61L implies that stimulation
of this lipid kinase by Ha-Ras can occur even if the Ras protein lacks
farnesyl. The increased binding of PI3-kinase to Ext61L, perhaps in
conjunction with improved access to membrane phosphatidylinositols,
appears sufficient to explain this enhancement. B-Raf can also bind
Ext61L quite well, implying that a farnesyl group is not a requirement
for binding of this second effector.
However, the most unexpected feature of Ext61L signaling was that the
increased physical interaction between Ext61L and B-Raf was not
translated into increased B-Raf activity. In vitro assays detected moderate B-Raf activity in cells expressing Ext61L, and in
intact cells the MEK/ERK pathway was still functional, and its activity
was required, as shown by inhibition of neurite outgrowth with PD98059.
However, neither B-Raf nor its pathways were stimulated by Ext61L as
well as by native Ha-Ras61L. Such impairment could arise indirectly
from the hyperactivation of the PI3-kinase. The phospholipid-stimulated
kinase Akt has recently been reported to phosphorylate and inhibit
Raf-1 (68).
A second intriguing possibility is that B-Raf is poorly activated
because Ext61L lacks a farnesyl. Recent studies have demonstrated that
full activation of Raf-1 requires interaction of the Raf-1 cysteine-rich domain with Ras (22, 69). The Raf- cysteine-rich domain
interaction with Ha-Ras is distinct from the interaction with the
classical effector domain and independent of the guanine nucleotide
state of Ha-Ras and seems to require C-terminal post-translational lipid modification of Ha-Ras. Additional reports indicate that there is
a structural conformation present in the prenylated form of Ha-Ras that
is needed to induce full activity of Raf-1 and B-Raf (19, 69). The
suboptimal activation of B-Raf by a nonfarnesylated Ext61L tends to
support this model. It is not yet clear if this "structure" is the
farnesyl group itself needed for a direct physical interaction with the
Raf protein or if it is a conformation of the broader C-terminal domain
that is induced by the presence of a farnesyl group (and palmitate) and
their interaction with the lipid bilayer. Because Ext61L maintains an
interaction with membranes through the C-terminal domain, this
nonfarnesylated protein provides an excellent tool to study the
contributions of a farnesyl group to Ras-effector interactions and the
effects of its absence in the physiological context of the intact cell.
To study the role of the C terminus in Ha-Ras signaling, both membrane
binding and activity must be retained. In contrast to the poor or even
absent activity seen with previous C-terminal mutants, Ext61L displays
membrane binding and strong biological function and thus provides the
first available model for testing the roles of the farnesyl group and
palmitates in the setting of the intact cell. The unbalanced effector
utilization induced by Ext61L shows that changes in the lipidation and
C-terminal residues of Ha-Ras can also be used to manipulate signaling
of PI3-kinase and B-Raf. Using further alterations of the C terminus it
may be possible to develop biologically functional, pathway-selective Ras proteins. It may eventually be possible to use the C terminus or
mimics of its structure to interfere with specific, oncogenic Ras
signaling pathways.
 |
ACKNOWLEDGEMENTS |
Plasmids utilized in these studies were
kindly provided by Gary Bokoch, Gideon Bollag, Lawrence Quilliam, and
Geoff Clark. Lee Graves generously supplied recombinant MEK and
recombinant ERK proteins and advice on the B-Raf kinase assay; F. Anderson Norris willingly provided much help for the PI3-kinase assays and also the inositol-4-phosphatase cDNA. The authors also thank Sharon Campbell, Channing Der, and Marc Symons for their experimental advice and helpful comments on the manuscript.
 |
FOOTNOTES |
*
This work was supported by funds (to J.E.B.) from the Roy
J. Carver Charitable Trust, the Elsa U. Pardee Foundation, and
NSF Professional Opportunities for Women in Research and
Education Award MCB 9973378.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: 3212 Molecular
Biology Bldg., Iowa State University, Ames, IA 50011. Tel.:
515-294-6125; Fax: 515-294-0453; E-mail: jbuss@iastate.edu.
Published, JBC Papers in Press, May 8, 2000, DOI 10.1074/jbc.M001368200
2
M. A. Booden and J. E. Buss,
unpublished results.
3
M. A. Booden and J. E. Buss,
unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
PI3-kinase, phosphatidylinositol 3-kinase;
HA, hemagglutinin;
4-Ptase, inositol
4-phosphatase;
DRM, detergent-resistant membrane;
PAGE, polyacrylamide
gel electrophoresis;
MEK, mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase;
ERK, extracellular
signal-regulated kinase;
PAK, p21-activated kinase;
PtdIns, phosphatidylinositol.
 |
REFERENCES |
| 1.
|
Lowy, D. R.,
and Willumsen, B. M.
(1993)
Annu. Rev. Biochem.
62,
851-891
|
| 2.
|
Rodriguez-Viciana, P.,
Warne, P. H.,
Dhand, R.,
Vanhaesebroeck, B.,
Gout, I.,
Fry, M. J.,
Waterfield, M. D.,
and Downward, J.
(1994)
Nature
370,
527-532
|
| 3.
|
Rodriguez-Viciana, P.,
Warne, P. H.,
Vanhaesebroeck, B.,
Waterfield, M. D.,
and Downward, J.
(1996)
EMBO J.
15,
2442-2451
|
| 4.
|
Klippel, A.,
Escobedo, J. A.,
Hirano, M.,
and Williams, L. T.
(1994)
Mol. Cell. Biol.
14,
2675-2685
|
| 5.
|
Kikuchi, A.,
and Williams, L. T.
(1996)
J. Biol. Chem.
271,
588-594
|
| 6.
|
Warne, P. H.,
Viciana, P. R.,
and Downward, J.
(1993)
Nature
364,
352-355
|
| 7.
|
Vojtek, A. B.,
Hollenberg, S. M.,
and Cooper, J. A.
(1993)
Cell
74,
205-214
|
| 8.
|
Campbell, S. L.,
Khosravi-Far, R.,
Rossman, K. L.,
Clark, G. J.,
and Der, C. J.
(1998)
Oncogene
17,
1395-1413
|
| 9.
|
Katz, M. E.,
and McCormick, F.
(1997)
Curr. Opin. Gen. Dev.
7,
75-79
|
| 10.
|
Wittinghofer, A.,
and Nassar, N.
(1996)
Trends Biochem. Sci.
21,
488-491
|
| 11.
|
Cox, A. D.,
and Der, C. J.
(1997)
Biochim. Biophys. Acta Rev. Cancer
1333,
F51-F71
|
| 12.
|
Zhang, F. L.,
and Casey, P. J.
(1996)
Annu. Rev. Biochem.
65,
241-269
|
| 13.
|
Choy, E.,
Chiu, V. K.,
Silletti, J.,
Feoktistov, M.,
Morimoto, T.,
Michaelson, D.,
Ivanov, I. E.,
and Philips, M. R.
(1999)
Cell
98,
69-80
|
| 14.
|
Cadwallader, K. A.,
Paterson, H.,
MacDonald, S. G.,
and Hancock, J. F.
(1994)
Mol. Cell. Biol.
14,
4722-4730
|
| 15.
|
Dudler, T.,
and Gelb, M. H.
(1996)
J. Biol. Chem.
271,
11541-11547
|
| 16.
|
Hancock, J. F.,
Paterson, H.,
and Marshall, C. J.
(1990)
Cell
63,
133-139
|
| 17.
|
Willumsen, B. M.,
Cox, A. D.,
Solski, P. A.,
Der, C. J.,
and Buss, J. E.
(1996)
Oncogene
13,
1901-1909
|
| 18.
|
Hu, C.-D.,
Kariya, K.,
Tamada, M.,
Akasaka, K.,
Shirouzu, M.,
Yokoyama, S.,
and Kataoka, T.
(1995)
J. Biol. Chem.
270,
30274-30277
|
| 19.
|
Luo, Z.,
Diaz, B.,
Marshall, M. S.,
and Avruch, J.
(1997)
Mol. Cell. Biol.
17,
46-53
|
| 20.
|
Brtva, T. R.,
Drugan, J. K.,
Ghosh, S.,
Terrell, R. S.,
Campbell-Burk, S.,
Bell, R. M.,
and Der, C. J.
(1995)
J. Biol. Chem.
270,
9809-9812
|
| 21.
|
Drugan, J. K.,
Khosravi-Far, R.,
White, M. A.,
Der, C. J.,
Sung, Y. J.,
Hwang, Y. W.,
and Campbell, S. L.
(1996)
J. Biol. Chem.
271,
233-237
|
| 22.
|
Roy, S.,
Lane, A.,
Yan, J.,
McPherson, R.,
and Hancock, J. F.
(1997)
J. Biol. Chem.
272,
20139-20145
|
| 23.
|
Rubio, I.,
Wittig, U.,
Meyer, C.,
Heinze, R.,
Kadereit, D.,
Waldmann, H.,
Downward, J.,
and Wetzker, R.
(1999)
Eur. J. Biochem.
266,
70-82
|
| 24.
|
Bhattacharya, S.,
Chen, L.,
Broach, J. R.,
and Powers, S.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
2984-2988
|
| 25.
|
Kuroda, Y.,
Noburu, S.,
and Kataoka, T.
(1993)
Science
259,
683-686
|
| 26.
|
Voice, J.,
Klemke, R.,
Le, A.,
and Jackson, J.
(1999)
J. Biol. Chem.
274,
17164-17170
|
| 27.
|
Yan, J.,
Roy, S.,
Apolloni, A.,
Lane, A.,
and Hancock, J. F.
(1998)
J. Biol. Chem.
273,
24052-24056
|
| 28.
|
Booden, M. A.,
Baker, T. L.,
Solski, P. A.,
Der, C. J.,
Punke, S. G.,
and Buss, J. E.
(1999)
J. Biol. Chem.
274,
1423-1431
|
| 29.
|
Sells, M. A.,
Knaus, U. G.,
Bagrodia, S.,
Ambrose, D. M.,
Bokoch, G. M.,
and Chernoff, J.
(1997)
Curr. Biol.
7,
202-210
|
| 30.
|
Miller, J.,
and Germain, R. N.
(1986)
J. Exp. Med.
164,
1478-1489
|
| 31.
|
Kozma, R.,
Sarner, S.,
Ahmed, S.,
and Lim, L.
(1997)
Mol. Cell. Biol.
17,
1201-1211
|
| 32.
|
Daniels, R. H.,
Hall, P. S.,
and Bokoch, G. M.
(1998)
EMBO J.
17,
754-764
|
| 33.
|
Buss, J. E.,
Solski, P. A.,
Schaeffer, J. P.,
MacDonald, M. A.,
and Der, C. J.
(1989)
Science
243,
1600-1603
|
| 34.
|
Zheng, Y.,
Bagrodia, S.,
and Cerione, R. A.
(1994)
J. Biol. Chem.
269,
18727-18730
|
| 35.
|
Schroeder, R. J.,
Ahmed, S. N.,
Zhu, Y.,
London, E.,
and Brown, D. A.
(1998)
J. Biol. Chem.
273,
1150-1157
|
| 36.
|
Vaillancourt, R. R.,
Gardner, A. M.,
and Johnson, G. L.
(1994)
Mol. Cell. Biol.
14,
6522-6530
|
| 37.
|
Li, X.,
Lee, J. W.,
Graves, L. M.,
and Earp, H. S.
(1998)
EMBO J.
17,
2574-2583
|
| 38.
|
Greene, L. A.,
and Tischler, A. S.
(1982)
Adv. Cell. Neurobiol.
3,
373-414
|
| 39.
|
Bar-Sagi, D.,
and Feramisco, J. R.
(1985)
Cell
42,
841-848
|
| 40.
|
Guerrero, I.,
Wong, H.,
Pellicer, R.,
and Burstein, D. E.
(1986)
J. Cell. Physiol.
129,
71-76
|
| 41.
|
Gallo, G.,
and Letourneau, P. C.
(1998)
Curr. Biol.
8,
80-82
|
| 42.
|
Khosravi-Far, R.,
Campbell, S.,
Rossman, K. L.,
and Der, C. J.
(1998)
Adv. Cancer Res.
72,
57-107
|
| 43.
|
Westwick, J. K.,
Lambert, Q. T.,
Clark, G. J.,
Symons, M.,
Van Aelst, L.,
Pestell, R. G.,
and Der, C. J.
(1997)
Mol. Cell. Biol.
17,
1324-1335
|
| 44.
|
Qiu, R.,
Chen, J.,
Kirn, D.,
McCormick, F.,
and Symons, M.
(1995)
Nature
374,
457-459
|
| 45.
|
Joneson, T.,
White, M. A.,
Wigler, M. H.,
and Bar-Sagi, D.
(1996)
Science
271,
810-812
|
| 46.
|
Qiu, R.,
Chen, J.,
McCormick, F.,
and Symons, M.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11781-11785
|
| 47.
|
Khosravi-Far, R.,
Solski, P. A.,
Clark, G. J.,
Kinch, M. S.,
and Der, C. J.
(1995)
Mol. Cell. Biol.
15,
6443-6453
|
| 48.
|
Gebbink, M. F.,
Kranenburg, O.,
Poland, M.,
van Horck, F. P.,
Houssa, B.,
and Moolenaar, W. H.
(1997)
J. Cell Biol.
137,
1603-1613
|
| 49.
|
Hawkins, P. T.,
Eguinoa, A.,
Qiu, R. G.,
Stokoe, D.,
Cooke, F. T.,
Walters, R.,
Wennstrom, S.,
Claesson-Welsh, L.,
Evans, T.,
Symons, M.,
and Stephens, L.
(1995)
Curr. Biol.
5,
393-403
|
| 50.
|
Boriak-Sjodin, P. A.,
Margait, S. M.,
Bar-Sagi, D.,
and Kuriyan, J.
(1998)
Nature
394,
337-343
|
| 51.
|
Han, J. K.,
Luby-Phelps, K.,
Das, B.,
Shu, X.,
Xia, Y.,
Mosteller, R. D.,
Krishna, U. M.,
Falck, J. R.,
White, M. A.,
and Broek, D.
(1998)
Science
279,
558-560
|
| 52.
|
Bansal, V. S.,
Caldwell, K. K.,
and Majerus, P. W.
(1990)
J. Biol. Chem.
265,
1806-1811
|
| 53.
|